ImCheck Therapeutics designs and develops immunotherapeutic antibodies for the treatment of cancer and autoimmune disease.
ImCheck Therapeutics has raised $22.4M in total funding. The most recent round was Grant. The last funding was announced in August 2024.
ImCheck Therapeutics's investors include Bpifrance, Earlybird Venture Capital, Wellington Partners, Andera Partners, EQT Life Sciences.
ImCheck Therapeutics is headquartered in Marseille, France.
ImCheck Therapeutics designs and develops immunotherapeutic antibodies for the treatment of cancer and autoimmune disease.
ImCheck Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ImCheck Therapeutics — Funding & Investors." VCBacked, August 29, 2024, https://www.vcbacked.co/company/imcheck-therapeutics. Accessed July 31, 2026.
VCBacked. (2024). ImCheck Therapeutics — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/imcheck-therapeutics
{{cite web |title=ImCheck Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/imcheck-therapeutics |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated